Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRVS
CUSIPN/A
Phone650-900-4520
Debt
Debt-to-Equity RatioN/A
Current Ratio13.69
Quick Ratio13.69
Price-To-Earnings
Trailing P/E Ratio-3.94
Forward P/E Ratio-3.99
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.03 per share
Price / Book2.62
Profitability
EPS (Most Recent Fiscal Year)($2.72)
Net Income$-55,660,000.00
Net MarginsN/A
Return on Equity-51.29%
Return on Assets-46.52%
Miscellaneous
Employees55
Outstanding Shares29,190,000
Market Cap$293.68
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) released its quarterly earnings results on Thursday, May, 3rd. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.11. View Corvus Pharmaceuticals' Earnings History.
What price target have analysts set for CRVS?
4 Wall Street analysts have issued 12 month price objectives for Corvus Pharmaceuticals' stock. Their predictions range from $14.00 to $26.00. On average, they anticipate Corvus Pharmaceuticals' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price. View Analyst Ratings for Corvus Pharmaceuticals.
What is the consensus analysts' recommendation for Corvus Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Esperion Therapeutics (ESPR), Endocyte (ECYT), Tricida (TCDA), Wave Life Sciences (WVE), Intra-Cellular Therapies (ITCI), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS), OptiNose (OPTN), Flexion Therapeutics (FLXN), Dynavax Technologies (DVAX), Omeros (OMER), CytomX Therapeutics (CTMX), Epizyme (EPZM) and Karyopharm Therapeutics (KPTI).
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller M.D., Co-Founder, Chairman, Chief Exec. Officer and Pres (Age 67)
- Dr. Peter A. Thompson, Co-Founder and Director (Age 58)
- Mr. Leiv Lea, CFO & Chief Bus. Officer (Age 64)
- Dr. Joseph J. Buggy Ph.D., Co-Founder and Strategic Advisor (Age 51)
- Mr. Daniel W. Hunt, Sr. VP & Chief Bus. Officer
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
Has Corvus Pharmaceuticals been receiving favorable news coverage?
News stories about CRVS stock have been trending somewhat positive on Friday, Accern Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corvus Pharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news articles about the company an impact score of 46.07 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $10.21.
How big of a company is Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a market capitalization of $293.68 million. The company earns $-55,660,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Corvus Pharmaceuticals employs 55 workers across the globe.
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
